The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Where Summit Therapeutics ( SMMT -7.92%) falls on that spectrum is a big question mark right now. It has been among the hottest healthcare stocks to own over the past 12 months, as its valuation has ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands among Wednesday’s ...

Leveragen has announced a strategic partnership with Moonlight Bio, targeting the development of T-cell therapies for ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...